Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Explore the evolving US housing market: trends in homebuilder confidence, construction growth, renter vs. owner dynamics, and the impact of tariffs on costs.

ENDO 2025 Tirzepatide Outperforms Semaglutide on Combined T2D Goals Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.